Search clinical trials for: YY201

Total 9 results

Shanghai Yuyao Biotech Co., Ltd.

Recruiting

An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies

Advanced Solid Tumor | Hematological Malignancy

China
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Not yet recruiting

A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis
Shanghai Yuyao Biotech Co., Ltd.

Active, not recruiting

An Phase I Study of YY001 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Not yet recruiting

A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors

Advanced Solid Tumors

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Metastatic Castration-resistant Prostate Cancer (mCRPC)

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Study YL201 in Patients With Selected Advanced Solid Tumors

Advanced Solid Tumor

China
Yooyoung Pharmaceutical Co., Ltd.

Withdrawn

Clinical Trial of YY1201 for Treatment of Osteoarthritis of the Knee

Osteoarthritis, Knee

Korea, Republic of
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Study of YL201 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States, China
Chongqing Claruvis Pharmaceutical Co., Ltd.

Completed

A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China

Search clinical trials for: YY201

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations